Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 6/20 | 0.34 |
| ▸ | PTGER3 | P43115 | 6/20 | 0.34 |
| ▸ | PTGER1 | P34995 | 5/20 | 0.34 |
| ▸ | PTGER2 | P43116 | 5/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.33 |
| ▸ | PLA2G2A | P14555 | 4/20 | 0.32 |
| ▸ | PLA2G10 | O15496 | 3/20 | 0.32 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.30 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.30 |
| ▸ | FYN | P06241 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7379228 | 0.70 | PIM1 (0.38) | PARP1PIM1PIM3AURKB | |
| Carbamic Acid SCHEMBL27894860 | 0.69 | CYP1A2 (0.45) | PARP1MAPK1 | |
| SCHEMBL31310168 | 0.69 | GRIN2D (0.48) | PLA2G2APLA2G10 | |
| SCHEMBL3363233 | 0.68 | HPGD (0.44) | MAPK1 | |
| SCHEMBL3065165 | 0.68 | PARP1 (0.46) | PARP1MAPK1PIM1PIM3AURKB | |
| SCHEMBL31422520 | 0.68 | PIM1 (0.33) | PARP1PIM1PIM3AURKB | |
| SCHEMBL950000 | 0.68 | FFAR1 (0.39) | PLA2G2APLA2G10SLCO1B1PARP1PIM1 | |
| SCHEMBL28665677 | 0.68 | BCAT2 (0.51) | PARP1AURKB | |
| SCHEMBL1557945 | 0.68 | PIM1 (0.34) | PIM1PIM3AURKB | |
| SCHEMBL4655029 | 0.67 | GP6 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1841504-B1 | SUBSTITUTED BIARYL COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-11-19 | — | — | EP | disclosed |
| US-7645799-B2 | Substituted biaryl compounds as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-12 | — | — | US | disclosed |
| US-20090062287-A1 | SUBSTITUTED BIARYL COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-03-05 | — | — | US | disclosed |
| US-7459564-B2 | Substituted biaryl compounds as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-02 | — | — | US | disclosed |
| US-20060154915-A1 | Substituted biaryl compounds as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154915-A1 | Substituted biaryl compounds as factor XIa inhibitors | TFPI, F3, F12 | PTGER4 1716/4885PTGER3 377/4885PTGER1 1612/4885 |
| US-20090062287-A1 | SUBSTITUTED BIARYL COMPOUNDS AS FACTOR XIA INHIBITORS | TFPI, F3, F12 | PTGER4 1716/4885PTGER3 377/4885PTGER1 1612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.